4D Molecular Therapeutics
Update in progressFDMT (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
4D Molecular Therapeutics is a late‑stage biotech developing adeno-associated virus vectors through its Therapeutic Vector Evolution platform in the U.S. and the Netherlands. Its lead candidate, 4D‑150, targets retinal vascular diseases by enabling multi‑year anti‑VEGF production in the retina via intravitreal injection for wet AMD and diabetic macular edema. Additional programs include 4D‑710 (cystic fibrosis) and 4D‑175 (geographic atrophy). Partners include Otsuka. Founded 2013; Emeryville, CA.
Company score
- Sentiment
- 0.33
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.17
- Governance
- 0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.20
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!